openPR Logo
Press release

Major Advancements| Competitor Landscape: Rheumatoid Arthritis

Major Advancements| Competitor Landscape: Rheumatoid

Researchmoz added Most up-to-date research on "Competitor Landscape: Rheumatoid Arthritis" to its huge collection of research reports.

Competitor Landscape: Rheumatoid Arthritis


Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the Rheumatoid Arthritis (RA) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharmas view of the disease landscape
- Landscape Updates: Order of Entry analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved products lifecycle management initiatives; Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019

To Get Sample Copy of Report visit @

Key Highlights

- If the results of the Phase II MANTA safety trial are required by the FDA prior to filing for regulatory approval of filgotinib for RA, this could delay US approval by 2 years
- Given that the Phase II NCT03241108 trial is limited to 90 patients in the EU, it is likely that NovImmune will need to initiate a second Phase II trial with a larger number of patients, including US patients, prior to proceeding with a Phase III program for NI-0101 in RA
- The Phase II trial assessing the immunogenicity and safety of Zostavax in RA patients using abatacept, if positive, is likely to boost physician opinion of abatacepts safety profile in RA, and reduce potential physician concerns that the use of abatacept may negatively impact the effectiveness of some immunizations, as suggested by its US FDA label.


- The briefing is based on Sociable Pharmas analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to buy

- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Get Complete TOC With Tables and Figures @

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948

Follow us on LinkedIn @

Follow me on @

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Major Advancements| Competitor Landscape: Rheumatoid Arthritis here

News-ID: 1493609 • Views:

More Releases for Phase

PanAfGeo: The Second Phase Begins!
The PanAfGeo community is pleased to announce the launching of the PanAfGeo second phase (PanAfGeo-2), which will continue to build on the first phase project’s achievements over the next three years. PanAfGeo, an EU co-funded initiative that began in 2016, contributed to the transfer of knowledge between European and African Geological Surveys. PanAfGeo also ensured the institutional strengthening of many African national administrations in charge of geology and mining. With the backing
COVID-19 - Pipeline Analysis 2020 for Global Market | Emphasis on Products cover …
COVID-19 (also known as Anderson COVID-19)?is a viral disease caused by RNA virus, SARS-CoV-2 or commonly known as corona virus. These viruses can cause respiratory, enteric, hepatic, and neurologic diseases. At the end of 2019, a new coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, China. It rapidly spread, resulting in an epidemic throughout China, followed by an increasing number of cases in other
Power Metering Market Information by type (smart, digital, analog), by phase (si …
Power Metering Market Information by type (smart, digital, analog), by phase (single phase, three phase) by application (residential, commercial and industrial) and Region - Forecast to 2022 The report for Global Power Metering Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and
HIV Vaccines Market Perceive Aggrandized Growth at a CAGR of 11.48% Till 2023 | …
HIV Vaccines Market Report Added on with Overall Analysis. Key developments and Strategies Cover in this Report. The Market for Expected to Grow Globally Over the CAGR of 5 % During the Period 2018 to 2027 from USD 2,702.3 Billion in 2027. HIV Vaccines Market - Segmentation The global HIV vaccines market has been segmented on the basis of basis of antibiotics, type, and lastly, region. Antibiotics have been segmented into dicloxacillin,
2026 Global Pharmacovigilance Market Growth Analysis by Clinical Trials Like Pre …
Global Pharmacovigilance Market 2018 report includes extensive Market analysis and industry landscape along with SWOT analysis and PESTEL analysis of the important vendors. The analysis is conducted with a blend of secondary and primary advice for inputs from participants in the industry. Pharmacovigilance industry report covers the prospects of Women’S Health P oducts in the forecast period of 2018-2026 and the scenario. Growing prevalence of adverse reactions caused by drugs, has
MAAT Inaugurates Versatile Phase Shifter
Company announces release of a digital recreation of Roger Schult’s analog hardware MAAT Incorporated, a manufacturer of exceptional performance professional audio solutions, today announced the release of RSPhaseShifter version 1.0, a digital implementation of the Roger Schult/German Audio Lab’s Phase Shifter 500 Series W2324 hardware. The cross–platform plug–in creates a high quality, phase shifted version of a monaural or stereo input. Available in formats for all major DAWs (Digital Audio Workstations), RSPhaseShifter